Updates from #ASCO23: mRCC & the CONTACT03 Trial

Exploring frontline and second-line treatment options for metastatic RCC including combinations of tyrosine kinase inhibitors and immunotherapy agents based on risk criteria. Analysis of the CONTACT03 Trial outcomes revealing no significant difference between PDL-1 monoclonal antibody with cabozantinib compared to cabozantinib alone. Insights on response rates, challenges in subgroup analysis, and toxicity profile in metastatic RCC patients post-progressing on prior treatment. Discussion on negative study results, subgroup analysis complexities, and impact on treatment paradigms in oncology trials.